omniture
logo
Search
云顶新耀医药科技有限公司 EVEREST MEDICINES
Media Room

Latest News

rss

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines

2022-01-04 08:00 5228

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

SHANGHAI, Dec. 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Providence Therapeutic...

2021-12-20 20:55 5082

Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

* TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to redu...

2021-12-16 08:49 5097

Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea

SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Everest Medicines

2021-12-15 08:00 4882

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therape...

2021-12-01 08:00 3921

Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index

SHANGHAI, Nov. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"...

2021-11-24 08:00 2891

Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index

SHANGHAI, Nov. 24, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"...

2021-11-24 08:00 3974

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint

SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD)...

2021-11-11 08:05 4487

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company...

2021-11-08 08:15 3924

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company...

2021-11-08 08:10 2775

Everest Medicines Announces Share Repurchase Transaction Details

SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company")...

2021-11-01 08:00 3385

Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, Sept. 29, 2021 /PRNewswire/ -- Everest Medicines

2021-09-29 17:44 4567
12345